Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial

BACKGROUND: Lung nodules are a diagnostic challenge, with an estimated yearly incidence of 1.6 million in the United States. This study evaluated the accuracy of an integrated proteomic classifier in identifying benign nodules in patients with a pretest probability of cancer (pCA) ≤ 50%. METHODS: A...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Chest
Autors principals: Silvestri, Gerard A., Tanner, Nichole T., Kearney, Paul, Vachani, Anil, Massion, Pierre P., Porter, Alexander, Springmeyer, Steven C., Fang, Kenneth C., Midthun, David, Mazzone, Peter J.
Format: Artigo
Idioma:Inglês
Publicat: American College of Chest Physicians 2018
Matèries:
Lung Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6689113/
https://ncbi.nlm.nih.gov/pubmed/29496499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chest.2018.02.012
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars